PRAME mRNA is a biomarker of metastasis risk for patients with class 1 uveal melanoma, according to authors of a retrospective study.
Detection of an epigenetic signature found in five different common tumor types—colon, lung, breast, stomach, and endometrial cancers—may be useful in diagnosing early-stage tumors using a blood test.
Researchers at the University of Missouri are now reporting that a gene thought to suppress cancer may actually promote metastatic disease in some patients with colorectal cancer.
Research scientists have developed a test that may be able to aid in the diagnosis of ovarian cancer at an early stage.
New studies are suggesting that there are novel associations between gene mutations and immune surveillance that could impact the response to immunotherapy in patients with lung cancer.
The enzyme ephrin receptor A2 (EphA2) normally blocks KRAS mutation-driven lung adenocarcinoma tumorigenesis, but a new study shows that EphA2 deletion mutation allows aggressive tumor growth—providing “important therapeutic targets” for this deadly form of lung cancer.
Germline BRCA2 mutations are associated with poorer outcome in prostate cancer and now researchers think they know why.
Researchers in Texas are now reporting that there may be a smarter way to combat cancer-associated KRAS (Kirsten rat sarcoma viral oncogene homolog) mutations and possibly attack specific tumor types in a new targeted manner.
A new finding shows that a specific biomarker may predict which HER2-negative breast cancer patients would benefit most from bevacizumab treatment.
A recent study published in the Journal of the American Medical Association (JAMA) revealed how BRCA testing is conducted and whether genetic counseling followed professional guidelines.